Login
$TLPH
$0.86 +$0.00 (0.0%) After hours

Company Executives

Officer Age In this role Joined 2025 pay Source
Vincent J. Angotti Also a director
Director, Chief Executive Officer
58 Not stated Not stated $1,117,277
Raffi Asadorian
Chief Financial Officer
56 Since 2017
9 years
Not stated $727,309
Shakil Aslam
Chief Medical Officer
61 Since 2024
2 years
2024 $654,840
Badri Dasu
Chief Engineering Officer
63 Since 2007
19 years
Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
8
serving now
Independent
0 of 1
stated in the proxy; 7 not stated
Average tenure
8.3 years
from year joined
CEO also chairs the board
No
Adrian Adams
Director Age On board Independent Committees Other public boards 2025 pay Source
Adrian Adams
75 Not stated Not stated
Nominating and Corporate Governance · Chair
Akebia Therapeutics, Inc. $50,932
Vincent J. Angotti
58 2017
9 years
Not independent None stated None stated Paid as CEO
Marina Bozilenko
60 2021
5 years
Not stated
Audit
SynAct Pharma AB $45,932
Joseph Todisco
50 2025
1 year
Not stated
Compensation
CorMedix, Inc. $51,726
Mark Wan
60 2006
20 years
Not stated
Compensation · Chair Nominating and Corporate Governance
None stated $45,932
Jill Broadfoot
65 2021
5 years
Not stated
Audit · Chair
Cue BioPharma, Inc. $43,432
Stephen J. Hoffman, M.D., Ph.D.
72 2010
16 years
Not stated
Audit Compensation
BYOMass Therapeutics, Inc. $42,807
Abhinav Jain
35 2024
2 years
Not stated
Compensation Nominating and Corporate Governance
Aytu BioPharma, Inc. $44,057

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Entities related to Nantahala Capital Management, LLC
holders of more than 5% of our outstanding capital stock
Amount not stated

Purchased pre-funded warrants in the January 2024 private placement

Investor Company ITF Rosalind Master Fund L.P.
holders of more than 5% of our outstanding capital stock
Amount not stated

Purchased pre-funded warrants in the January 2024 private placement

Entities related to Nantahala Capital Management, LLC
holders of more than 5% of our outstanding capital stock
Amount not stated

Purchased pre-funded warrants in the April 2025 private placement

Investor Company ITF Rosalind Master Fund L.P.
holders of more than 5% of our outstanding capital stock
Amount not stated

Purchased common stock and pre-funded warrants in the April 2025 private placement

Entities related to Nantahala Capital Management, LLC
holders of more than 5% of our outstanding capital stock
Amount not stated

Purchased common stock and pre-funded warrants in the September 2025 private placement

Investor Company ITF Rosalind Master Fund L.P.
holders of more than 5% of our outstanding capital stock
Amount not stated

Purchased common stock and pre-funded warrants in the September 2025 private placement

CorMedix Inc.
Approximately $17 million
2025

Purchaser in the September 2025 private placement, first closing

With Talphera Open in proxy
CorMedix Inc.
CorMedix Board Representative (Joseph Todisco, Class III Director)
Amount not stated

Board nomination right for CorMedix; Joseph Todisco appointed as CorMedix Board Representative

CorMedix Inc.
Amount not stated

Right of first negotiation over an acquisition of Talphera for 60 days after the public announcement of NEPHRO CRRT topline data

With Talphera Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support